M1FG
CSTL icon

Mach-1 Financial Group’s Castle Biosciences CSTL Stock Holding History

Mach-1 Financial Group’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,313
Closed -$267K – 234
2025
Q1 		$267K Buy
+13,313
New +$330K 0.08% 225
2023
Q4 		– Sell
-26,034
Closed -$440K – 239
2023
Q3 		$440K Buy
+26,034
New +$455K 0.18% 154

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Mach-1 Financial Group's CSTL Position: Q2 2025 in Review

Mach-1 Financial Group sold out of Castle Biosciences (CSTL) in Q2 2025, closing a stake of 13,313 shares — an estimated $267K sold.

Mach-1 Financial Group first reported a position in CSTL in Q3 2023 and held it in 2 quarters. The position peaked at $440K in Q3 2023. 152 funds tracked by Wall St. Rank hold CSTL as of Q2 2025.

  • Mach-1 Financial Group reported no remaining Castle Biosciences position as of Q2 2025 after selling out during the quarter.
  • Mach-1 Financial Group sold 13,313 Castle Biosciences shares in Q2 2025, an estimated $267K.
  • Mach-1 Financial Group first reported a position in Castle Biosciences in Q3 2023 and held it in 2 quarters.
  • Mach-1 Financial Group's Castle Biosciences position peaked at $440K in Q3 2023.
  • 152 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2025.

Based on Mach-1 Financial Group's 13F filing for Q2 2025, filed 11 Aug 2025.